Singapore markets open in 3 hours 48 minutes
  • Straits Times Index

    -15.15 (-0.49%)
  • S&P 500

    +41.45 (+0.95%)
  • Dow

    +338.48 (+1.00%)
  • Nasdaq

    +150.45 (+1.02%)

    +3,064.02 (+7.57%)
  • CMC Crypto 200

    +49.07 (+4.72%)
  • FTSE 100

    +102.39 (+1.47%)
  • Gold

    -9.80 (-0.55%)
  • Crude Oil

    +1.51 (+2.14%)
  • 10-Yr Bond

    +0.0120 (+0.91%)
  • Nikkei

    -200.31 (-0.67%)
  • Hang Seng

    +122.40 (+0.51%)
  • FTSE Bursa Malaysia

    -1.42 (-0.09%)
  • Jakarta Composite Index

    +47.51 (+0.78%)
  • PSE Index

    +9.53 (+0.14%)

Accelerator Life Science Partners Mourns the Loss of Senior Advisor and Friend, Tadataka "Tachi" Yamada, M.D.

·2-min read

SEATTLE, August 05, 2021--(BUSINESS WIRE)--Accelerator Life Science Partners ("ALSP"), a leading early-stage life science accelerator and investment firm, today acknowledged the sudden passing of senior advisor and board member, Tadataka (Tachi) Yamada, M.D., who died unexpectedly at home on August 4, 2021.

"We are saddened to share the news of Tachi’s unexpected passing," said Thong Q. Le, CEO and Senior Managing Director. "I have had the privilege and honor to have known and worked closely with Tachi for many years, and I was grateful to have the benefits of his knowledge, experience and leadership at ALSP. Tachi understood well the many challenges that early-stage biotechnology companies often face when developing disruptive technologies, and always reminded us to consider how the treatments we were developing would affect patients and (more broadly) global health. He is a 'giant among giants' when it comes to our life sciences industry, and his impact on patients and global health will be felt for many years to come. The ALSP team and I will miss Tachi dearly, and we send our deepest, most heartfelt sympathies to the Yamada family during this difficult time."

About Accelerator Life Science Partners

Accelerator Life Science Partners (ALSP) is an investment firm that catalyzes the development and commercialization of breakthrough biotechnology innovations by providing the complete business, scientific, and financial toolkit necessary for accelerating the establishment and operation of early-stage biotechnology companies. ALSP’s portfolio companies are backed by some of the world’s leading pharmaceutical companies and comprise of industry-leading, transformative companies, including Lodo Therapeutics (acquired by Zymergen), Lydian Neurosciences, Magnolia Neurosciences, Petra Pharma (acquired by a global pharmaceutical company), and Rodeo Therapeutics (acquired by Amgen Inc.). ALSP is a minority-owned firm that seeks to promote diversity and inclusion in the healthcare industry. For more information, please visit

View source version on


Accelerator Life Science Partners
Jessica Burback –
T: 206-234-6481

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting